跳至主要内容
临床试验/NCT00481390
NCT00481390已完成不适用

Prospective Epidemiological Study of the Prevalence of HLA-B*5701 in HIV-1 Infected Patients

GlaxoSmithKline1 个研究点 分布在 1 个国家目标入组 1,110 人开始时间: 2007年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,110
试验地点
1
主要终点
Prevalence of HLA-B*5701 in European HIV-1 population

研究概览

简要总结

This study is a cross-sectional observational study to evaluate the prevalence of HLA-B*5701 in the European area and in major European ethnotypes.

Any HIV-1 infected patient will be eligible for this study including treatment naïve and experienced patients, as well as patients previously tested for HLA-B*5701. Patients will be approached during a standard clinic visit, and will be consented prior to any study specific procedure. They will be asked to provide a tissue sample (cheek cells and blood sample) which will be used to assess HLA-B*5701 status by local and central laboratories.

In selected sites patients may be asked to provide an additional blood sample. This sample will be used to develop and validate different methodologies for assessing HLA-B*5701 status.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Prevalence of HLA-B*5701 in European HIV-1 population

次要结局

  • Prevalence of HLA-B*5701 in major European ethnotypes

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验